June 3 (Reuters) - Vaccines for COVID-19 being developed
and manufactured for the 2024-2025 campaign should target one of
the currently dominant JN.1 variants and JN.1-derived
subvariants such as KP.2, the U.S. Food and Drug
Administration's staff reviewers said on Monday.